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Review Article
An emerging place for lung cancer genomics in 2013
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ABSTRACT

KEY WORDS

Lung cancer is a disease with a dismal prognosis and is the biggest cause of cancer deaths in many countries. Nonetheless,
rapid technological developments in genome science promise more effective prevention and treatment strategies. Since
the Human Genome Project, scientific advances have revolutionized the diagnosis and treatment of human cancers,
including thoracic cancers. The latest, massively parallel, next generation sequencing (NGS) technologies offer much
greater sequencing capacity than traditional, capillary-based Sanger sequencing. These modern but costly technologies
have been applied to whole genome-, and whole exome sequencing (WGS and WES) for the discovery of mutations
and polymorphisms, transcriptome sequencing for quantification of gene expression, small ribonucleic acid (RNA)
sequencing for microRNA profiling, large scale analysis of deoxyribonucleic acid (DNA) methylation and chromatin
immunoprecipitation mapping of DNA-protein interaction.
With the rise of personalized cancer care, based on the premise of precision medicine, sequencing technologies are
constantly changing. To date, the genomic landscape of lung cancer has been captured in several WGS projects. Such work
has not only contributed to our understanding of cancer biology, but has also provided impetus for technical advances that
may improve our ability to accurately capture the cancer genome. Issues such as short read lengths contribute to sequenced
libraries that contain challenging gaps in the aligned genome. Emerging platforms promise longer reads as well as the ability
to capture a range of epigenomic signals. In addition, ongoing optimization of bioinformatics strategies for data analysis and
interpretation are critical, especially for the differentiation between driver and passenger mutations.
Moreover, broader deployment of these and future generations of platforms, coupled with an increasing bioinformatics
workforce with access to highly sophisticated technologies, could see many of these discoveries translated to the clinic at a
rapid pace. We look forward to these advances making a difference for the many patients we treat in the Asia-Pacific region
and around the world.
High-throughput nucleotide sequencing; genomics; lung neoplasms; non-small cell lung carcinoma (NSCLC); small cell
lung carcinoma (SCLC)

J Thorac Dis 2013;5(S5):S491-S497. doi: 10.3978/j.issn.2072-1439.2013.10.06

Introduction
Lung cancer is the most common and deadly (1) human cancer,
called “a global scourge” (2) with a dismal prognosis. The relative
5-year survival for patients with this disease is 14% (3), and has
remained largely unchanged for years.
Only recently had research interest focused on lung cancer,
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as more effective therapies have become available. Indeed, some
consider lung cancer to be a “poster boy” (4) for personalized
medicine. Much of this hope and hype comes from the potential
for advances in translational genomics to improve understanding
and management of this cancer.
Deoxyribonucleic acid (DNA) sequencing technologies
were introduced in the mid 1970s (5,6). W hen the first
human, naturally occurring tumorigenic somatic mutation
was discovered in 1982 (7), it became clear that sequencing
the cancer genome was a necessary next step (8). Completion
of the first human reference genome (9,10) then stimulated
technological advances which enabled the first human cancer
genome to be sequenced only four years later (11).
Sanger sequencing was first described in 1975 (5) as a “rapid
method for determining sequences in DNA”, by providing
accuracy and sequence contiguity that remains unmatched(12).
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Nowadays, the rapidity and scalability of next generations
sequencing (NGS) technologies are quickly improving our ability
to explore the cancer genome and exponentially advancing our
understanding of lung cancer pathogenesis, its diagnosis and
treatment (13-16).

Next generation technologies for whole genome
sequencing (WGS)
Past techniques for exploration of the cancer genome, such as
capillary electrophoresis based “Sanger” sequencing, array-based
genome-wide analysis of amplifications and deletions (17), gene
expression arrays (18) and retrovirus mediated expression
screening techniques, have successfully identified genomic
drivers of cancer (19-21), and novel therapeutic targets (20,22).
Commercially available since 2004, next generation sequencing
(NGS) platforms now provide high throughput, massively
parallel techniques able to generate sequence data orders of
magnitude more quickly, and at lower cost, than traditional
techniques (13,23).
Comprehensive genome sequencing techniques are now
used to study a range of genetic diseases (15). While many NGS
platforms require significant investments in infrastructure, they
share methodological similarities. Massively parallel sequencing
begins with the generation of a DNA library onto which platformspecific “adaptors” are bound. This library is then fixed to a solid
surface and each fragment is amplified so that the sequencing
reaction produces a detectable signal. The library is sequenced in a
series of automated, repetitive steps (14).
There are a large number of potential applications for NGS
technologies (24), such as WGS and whole exome sequencing
(WES) to find novel mutations (25); paired-end and mate-pair
sequencing to identify structural variations (26); targeted
resequencing for mutation discovery and validation (27);
transcriptome sequencing for quantification of gene expression
and discovery of transcribed mutations (28); small RNAsequencing for microRNA profiling (29); large scale analysis of
DNA methylation (30) and chromatin immunoprecipitation
for genomic mapping of DNA-protein interactions (31). It is
likely that there will be refinements in future that are not even
envisaged in these early days of genomic research.

NGS WGS of lung cancer
The advances of the past decade of genomics research demonstrate
the power of massive genomic surveys (15). The passion and
dedication with which large scale, comprehensive studies of the
human genome have been undertaken is second only to the fervor
and fecundity driving advances in requisite research infrastructure,
such as experimental technology, bioinformatics and ethics (32).
The spectrum of genomic changes seen in lung cancer is beyond

the scope of this brief overview, which will outline the methods
and studies used so far in the application of NGS technologies to
the study of this cancer.
Although early tools for genome-wide exploration provided
putative therapeutic targets, the majority of tumours still lacked
an identified molecular driver. The subsequent introduction of
NGS technologies has revolutionized our understanding of cancer
biology, the processes of carcinogenesis as well as its molecular
drivers, and the range of techniques with which to explore the
genome. The application of these platforms to the optimization
of lung cancer outcomes promises the potential to transform lung
cancer care.
Lung cancer—early steps towards personalized medicine
Before the development of massively parallel sequencing, much of our
understanding of the molecular pathology of lung cancer was based
on techniques such as mismatch repair detection (33), sequencing
of candidate genes (34), single nucleotide polymorphism (SNP)
arrays (21) and gene expression analysis (35). High throughput
sequencing technologies now enable comprehensive examination of
the lung cancer exome (36) and genome (37,38).
An important and key global, collaborative approach using
these technologies is led by The International Cancer Genome
Consortium (ICGC) and The Cancer Genome Atlas (TCGA) (39),
which bring the promise of a truly personalized approach to
cancer care, including the two major subtypes of lung cancer,
adenocarcinoma (AC) and squamous cell carcinoma (SCC), in
the first instance.
WGS of lung cancer
The first applications of massively parallel sequencing to the
study of lung cancer were understandably carefully designed and
focused studies (Table 1). In 2008, Campbell and colleagues
published the genomes of 2 lung cancer cell lines, 1 derived from
a neuroendocrine tumour and another from a small cell lung
cancer (SCLC) (26). The second sequence of a SCLC cell line
was published in 2010 (40). The first application of WGS to
DNA extracted from lung tumour paired with normal lung was
the same year by Lee et al. (38) Then, a second paired non-small
cell lung cancer (NSCLC)/normal lung sequence was published
in 2011, from a never-smoking patient with AC (37).
These initial WGS studies were performed using a range of
sequencing technologies (Table 2), including combinatorial
probe anchor ligation (cPAL) as well as the platforms of Illumina
and Life Technologies.
Illumina’s massively parallel sequencing technology is based on
sequencing by synthesis (47). After library preparation, sequencing
begins with the addition of a mixture of four nucleotides, each
labeled with a reversible terminator and base-specific fluorescent
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Table 1. Next generation sequencing studies of lung cancer to date.
First author

Year

Project design

Platform

Campbell (26)

2008

2 lung cancer cell lines WGS

Illumina Genome Analyzer

Pleasance (40)

2010

1 SCLC cell line WGS

SOLiD

Lee (38)

2010

1 NSCLC/normal lung pair WGS

Combinatorial probe anchor ligation

Ju (37)

2011

1 NSCLC/normal lung pair WGS

Illumina HiSeq and Genome Analyzer IIx

Imielinski (41)

2012

183 ACs and matched normal tissue;
Illumina HiSeq
159 WES, 23 WES + WGS, 1 WGS
The Caner Genome Atlas
2012
Integrated analysis of 178 SCCs and matched
Illumina HiSeq
Research Network (42)
germline; 19 WGS, 178 WES
Govindan (43)
2012
17 WGS; 16 adenocarcinoma and 1 large cell
Illumina Genome Analyzer II
carcinoma
WGS, whole genome sequencing; WES, whole exome sequencing; CNV, copy number variation; SNP, single nucleotide polymorphism; AC,
adenocarcinoma; SCC, squamous cell carcinoma; SCLC, small cell lung cancer; cPAL, combinatorial probe anchor ligation.

Table 2. Commercial next generation sequencing platforms for human whole genome sequencing.
Data processing
Read length/read time
Advantages

Disadvantages

Illumina: optical detection of fluorescently labeled nucleotides
2× 150 bp read
600 Gb;
Limited scalability; DNA
Illumina: HiSeq
Widely used; target difficult
length; 11 days
6 billion reads1
polymerase errors, slow
2500/2000 (44)2
genomic regions3
Illumina: Genome
2× 150 bp
85-95 Gb;
Widely used; target difficult
Lower data processing
Analyzer IIx (45)2
640 million reads1 genomic regions3
capacity than HiSeq
Life Technologies: optical detection of fluorescently labeled nucleotides using sequencing by oligonucleotide ligation and detection
10-15 Gb/day;
2-base encoding reduces errors Short read lengths
Mate paired: 2× 60 bp;
Paired-end: 75 bp and 35 bp;
fragment: 75 bp; 7 days
1
, paired end reads; 2, with TruSeq v3 kit; 3, TruSeq DNA PCR-Free Kit; bp, base pairs; Mb, megabase; Gb, gigabase; PCR, polymerase chain reaction.
Life Technologies:
SOLiD 5,500xl (46)

tag, and DNA polymerase. Fragments are extended one nucleotide
at a time, and after nucleotide incorporation, laser excitation and
image acquisition allow identification of the newly incorporated
nucleotide. The fluorescent tag and terminator are then removed,
and the next cycle of sequencing proceeds (47). Illumina’s range
of sequencing platforms available for WGS include the HiSeq and
Genome Analyzer IIx. The HiSeq offers both high output and
rapid run modes with paired end reads up to 150 bp generating up
to 600 Gb data in 11 days. By contrast, the Genome Analyzer IIx
can generate up to 95 Gb data by sequencing paired end reads of
150 bp in 14 days from as little as 50 ng DNA (45).
This platform is vulnerable to imperfections in DNA
polymerase activity which can result in nucleotide incorporation
errors (13), increasing the need for bioinformatic interpretation
of sequence results (48). Ongoing developments promise to
improve coverage of difficult genomic regions such those rich in
repeats, or in guanine (G) and cytosine (C). The TruSeq DNA
PCR-Free Kit removes the need for PCR amplification during
library preparation, reducing the risk of DNA polymerase-related
nucleotide incorporation errors and mis-representation of C-G

rich regions (49). In addition, Illumina acquired from Moleculo
in 2012 an innovative technology capable of reconstructing short
read data into long reads (50).
By contrast, Sequencing by Oligonucleotide Ligation and
Detection (SOLiD; Life Technologies) is driven by DNA ligase,
not DNA polymerase (51). The DNA library is amplified onto
paramagnetic beads immobilized on a solid substrate, a universal
primer is hybridized and sequencing commences. Nucleotide
octamers, fluorescently tagged at a specific base, are incorporated.
After ligation, image acquisition occurs in 4 channels to document
the nucleotide present at the identified base. The octamer is
then cleaved between bases 5 and 6, and the tag is removed in
preparation for the next round of sequencing. Consecutive cycles
sequence every 5th base (i.e., 5, 10, 15, 20 etc.); when complete,
the DNA is denatured and the process is repeated to sequence a
different set of nucleotide positions (i.e., 4, 9, 14, 19 etc.) (13, 24).
This system offers the potential for 2-base encoding. This is
achieved by incorporating fluorescent tags for adjacent bases
in the nucleotide octamer thus sequencing 2 adjacent bases.
Each base can then be interrogated twice, allowing detection of
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sequencing errors (24).
cPAL is a unique sequencing strategy that is commercially
available as a complete sequencing solution. Rolling circle
amplification is used to generate nanoballs of genomic DNA
that are adsorbed to a solid substrate in a nanoarray. Anchor
molecules bind to nucleotide adaptor sequences introduced
during library preparation. A fluorescently labeled probe
hybridizes to the template DNA and is ligated to the anchor.
Sequence is then read by detecting the fluorescence generated at
each ligation with great accuracy (52).
In a 2012 landmark paper, Imielinski et al., reported the
results of WGS of 36 pulmonary ACs/normal lung pairs coupled
with WES of an additional 92 pairs (41). WGS and WES were
performed with mean coverage of 69x and 91x, respectively.
A number of different techniques were used to identif y
potential driver mutations. It was found that a combination of
4 bioinformatics strategies optimally identified their ultimate
25 significantly mutated genes. Structural variation was also
explored in the 24 matched pairs for which WGS data was
available. This was the first publication of WGS data for multiple
lung tumours, and postulated a number of novel molecular drivers.
It was closely followed by the TCGA’s publication of the first
WGS analysis of SCC (42). This study investigated 178 WES
and 19 WGS performed on paired SCC/germline DNA. Whole
transcriptome profiling was also performed using integrated
RNA-sequencing and microarray data. Cases were distributed
among gene expression subtype signatures (53) that classified
tumours according to functional themes described in terms of
gene overexpression relative to the other subtypes.
WGS has also been used, in association with whole
transcriptome sequencing, to study the genomic differences
between NSCLC in smokers and never smokers (43). Govindan
et al., performed paired end WGS sequencing on 17 tumour/
normal lung pairs, including 16 ACs and a single large cell
carcinoma, with mean haploid coverage of 30x.
These studies suggest that application of NGS technologies
to the study of lung cancer genomes will assist us to unlock the
mysteries of this disease, and lead to improvements in outcomes
for patients. In addition to the identification of a number of
new putative therapeutic targets, WGS technology is fuelling
advances in metabolomics, epigenomics and transcriptomics. On
the other hand, in addition to the high cost currently, a number
of technical challenges are yet to be overcome.
Challenges facing lung cancer genomics
NGS technologies offer significant advantages over traditional
sequencing techniques for the field of WGS. However, a number
of the current platforms’ limitations have been identified and are
driving technological advances.
Traditional Sanger sequencing is a widely available, but
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meticulous and time-consuming process, and generally delivers
reads of around 1,000 bp with raw accuracy of 99.999% (24).
Newer NGS techniques generate large numbers of relatively
short reads using techniques which often require amplification by
PCR; these techniques are particularly vulnerable to systematic
error when applied to comprehensive genomic analysis (12).
Long sequences of repeated bases, degraded or damaged DNA
and C-G rich regions are particularly problematic (12). Indeed,
each sequencing platform has a unique profile of strengths and
weaknesses (54).
Short sequence read lengths are characteristic of the early NGS
technologies. Unfortunately, these can be troublesome to assemble
in a complete genome, and can create a biased aligned read that is
insensitive to repeat content and hinders systematic exploration
of the genetic basis of disease. Even the “complete reference” is
reported to contain up to 350 gaps (12). Regions of the genome
rich in repeats, such as those in proximity to centromeres and
telomeres, are particularly challenging to map with small reads
lengths. Sanger sequencing remains the method of choice for
characterising regions where NGS is suboptimal (55).
Genome regions that are rich in C and G can be prone to
erroneous replication by NGS technologies that are based on
PCR amplification because DNA polymerase ineffectively
amplifies these regions. Consequently, these can result in errors
in the DNA template delivered to the sequencer, and cause
systematic error in the generated reads. Assembly programs are
essential for sequence alignment and mapping, and share the
potential of sequencing platforms to confound results (56).
Without a doubt, these challenges are driving researchers to
achieve exponential advances in experimental and computational
technology. A variety of sample preparation technologies are now
available to help eliminate the need for template amplification
and generate reads of sufficient length to bridge repeat regions.
Another technological issue facing WGS bioinformaticians is
the intricate complexity of the mutational profile of lung cancer.
The computational bottleneck has progressed from generating
and aligning sequencing to bioinformatic analytics including
discrimination between driver and passenger mutations or
background ‘noise’.
The extremely large datasets generated by WGS projects have
meant that many investigators around the world are working on
strategies to optimally store, analyze and handle the “big data”.
A tiered approach to mutation classification appears of be quite
a useful way to classify the large number of mutations found in
these genomic interrogations (57). Tier 1 mutations include
changes in the coding regions of annotated exons, consensus
splice-site regions and RNA genes (including miRNA). Tier 2
features changes in conserved regions of the genome or those
with regulatory potential. Tier 3 is characterized by mutations in
nonrepetitive part of the genome that are not included in Tier 2.
The remainder of the genome is allocated to Tier 4. Common
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strategies for the differentiation of driver from passenger
mutations vary, but often include the selection of biologically
relevant, recurrent mutations. However, the definition of
“recurrent” remains inconsistent (41,58).
W hile these approaches assist in the interpretation of
mutation significance, they do not differentiate mutations from
background genome variation. The high mutation rate observed
in lung cancers disqualifies the bioinformatic assumption of a
uniform background mutation rate. However, computational
approaches adopted by TCGA in their WGS studies were able to
map the structure of variation in the background mutation rate
and account for this during data analysis (42).
Hanahan and Weinberg (59,60) proposed a framework of
“cancer hallmarks” which is increasingly extended and validated
by genomic discoveries. Systematically optimising methods for
genome sequencing, alignment, mapping and variant calling will
allow us to fully realise benefits of these advances for the study of
lung cancer biology.
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